STOCK TITAN

ARROWHEAD PHARMACEUTICALS (ARWR) SEC Filings, Jan-Apr 2026

ARWR NASDAQ
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
other
-
Schedule 13G/A
Rhea-AI Summary

The Vanguard GroupSchedule 13G/A reporting its holdings in Arrowhead Pharmaceuticals Inc.. The filing states amount beneficially owned: 0 shares and percent of class: 0%. It explains an internal realignment on January 12, 2026 and that certain Vanguard subsidiaries now report holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
ownership
-
Rhea-AI Summary

Arrowhead Pharmaceuticals reported results of its 2026 annual stockholder meeting. Stockholders elected seven directors to the board, with vote totals for each nominee ranging from about 70.4 million to 100.8 million votes in favor.

Stockholders rejected the advisory Say-on-Pay proposal, with 41,625,740 votes for and 59,963,903 votes against, signaling dissatisfaction with executive compensation. They approved the Amended and Restated 2021 Incentive Plan and ratified KPMG LLP as independent auditors. As of the January 22, 2026 record date, 140,010,690 common shares were outstanding and entitled to vote.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.60%
Tags
current report
Rhea-AI Summary

Arrowhead Pharmaceuticals' Chief Medical Officer sells shares under a preset plan. Chief Medical Officer James C. Hamilton executed an open-market sale of 10,000 shares of Arrowhead Pharmaceuticals common stock at a weighted average price of $64.19 per share on March 5, 2026, under a Rule 10b5-1 trading plan. After this transaction, he directly owned 236,958 shares, which include previously reported restricted stock units that remain subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
insider
-
Rhea-AI Summary

ARWR filed a Form 144 reporting a proposed sale of 10,000 common shares to be sold through Merrill Lynch (75 Rockefeller Plaza). The filing lists an aggregate value of $641,870.05 and a transaction date of 03/05/2026. The notice identifies the sale reason as Compensation with an effective date of 01/05/2025.

The filing also records prior sales: James Hamilton sold 40,164 common shares on 01/05/2026 for $2,534,478.03, listed under "Securities Sold During The Past 3 Months."

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.94%
Tags
other
-
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. reported a sharp turnaround for the quarter ended December 31, 2025, with revenue of $264.0 million driven mainly by collaboration payments, compared with $2.5 million a year earlier. Net income attributable to the company was $30.8 million, versus a loss of $173.1 million.

Results were boosted by $229.5 million in revenue from Sarepta milestones and research, and $34.2 million from a new Novartis collaboration. Arrowhead ended the quarter with $201.6 million in cash, cash equivalents and restricted cash and $715.0 million in available-for-sale securities. The FDA approved REDEMPLO for Familial Chylomicronemia Syndrome, giving the company its first commercial RNAi product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
quarterly report
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. filed a current report to note that it has announced and discussed its fiscal 2026 financial results for the period ended December 31, 2025. These results were shared through a press release dated February 5, 2026.

The press release is provided as Exhibit 99.1 and is designated as “furnished” rather than “filed,” which limits its use in certain legal contexts. The company also included an Inline XBRL cover page data file as Exhibit 104, signed on behalf of Arrowhead by Chief Financial Officer Daniel Apel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
annual report
-
Rhea-AI Summary

Arrowhead Pharmaceuticals is asking stockholders to approve several items at its virtual annual meeting on March 19, 2026, including board elections, a say-on-pay vote, ratification of KPMG as auditor, and an amended 2021 Incentive Plan. The plan would add 10,500,000 shares for equity awards and extend the plan term to January 2036, supporting long‑term stock-based compensation for employees, directors, and advisors.

The proxy highlights a majority‑independent board with a lead independent director, fully independent key committees, and a focus on environmental, social, and cybersecurity oversight. It also describes 2025 business achievements, including FDA approval of REDEMPLO for familial chylomicronemia syndrome, additional regulatory approvals abroad, major R&D and partnering milestones, and capital raises through convertible notes, common stock, and pre‑funded warrants totaling $930 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
proxy
Rhea-AI Summary

BlackRock, Inc. has filed an amended Schedule 13G reporting a large passive stake in Arrowhead Pharmaceuticals Inc.. As of 12/31/2025, BlackRock reports beneficial ownership of 20,323,221 shares of Arrowhead common stock, representing 15.0% of the outstanding class. BlackRock has sole voting power over 20,124,285 shares and sole dispositive power over 20,323,221 shares, with no shared voting or dispositive power.

The filing aggregates holdings across certain BlackRock business units and notes that one holder, iShares Core S&P Small-Cap ETF, on its own holds more than five percent of Arrowhead’s common stock. BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arrowhead.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
ownership

FAQ

How many ARROWHEAD PHARMACEUTICALS (ARWR) SEC filings are available on StockTitan?

StockTitan tracks 79 SEC filings for ARROWHEAD PHARMACEUTICALS (ARWR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for ARROWHEAD PHARMACEUTICALS (ARWR)?

The most recent SEC filing for ARROWHEAD PHARMACEUTICALS (ARWR) was filed on November 12, 2026.